Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT00101010. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating older patients with diffuse large B-cell lymphoma.
Study identification
- NCT ID
- NCT00101010
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Filgrastim Biological
- Pegfilgrastim Biological
- Rituximab Biological
- Cyclophosphamide Drug
- Pegylated liposomal doxorubicin hydrochloride Drug
- Prednisone Drug
- Vincristine Sulfate Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 61 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Oct 18, 2020
2005 – 2014
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hembree Mercy Cancer Center at St. Edward Mercy Medical Center | Fort Smith | Arkansas | 72913 | — |
| CCOP - Grand Rapids | Grand Rapids | Michigan | 49503 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| Cancer Research for the Ozarks | Springfield | Missouri | 65804 | — |
| Hematology Oncology Associates of Central New York, PC - Northeast Center | East Syracuse | New York | 13057-4510 | — |
| CCOP - Upstate Carolina | Spartanburg | South Carolina | 29303 | — |
| University of Texas M.D. Anderson CCOP Research Base | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00101010, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 18, 2020 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00101010 live on ClinicalTrials.gov.